Fibroblast growth factor 23 and cardiovascular events in chronic kidney disease patients

Implication for health policy/practice/research/medical education

Disorders of phosphate homeostasis are popular in patients with chronic renal failure. As renal function deteriorates, circulating levels of phosphate and the phosphate-regulatory hormone, fibroblast growth factor (FGF)-23, increase gradually. Higher serum levels of phosphate and FGF 23 are accompanied with an increased risk of adverse outcomes, comprising all-cause mortality and cardiovascular disease. The association of higher levels of FGF 23 and adverse cardiovascular outcomes are commonly independent of serum phosphate levels. High levels of FGF-23, hyperparathyroidism, and hyperphosphatemia have all been related to an increased risk of cardiovascular mortality and morbidity chronic renal failure individuals.

Please cite this paper as: Yaghoubi F. Fibroblast growth factor 23 and cardiovascular events in chronic kidney disease patients. J Parathyr Dis. 2016;4(1):11-12.